Batavia Biosciences Receives Grant from the Bill & Melinda Gates Foundation to Support Vaccine Availability in Developing Countries
Advanced cell-line technology could reduce costs of vaccine production
Leiden, The Netherlands, and Woburn, MA, 9th June 2016
Batavia Biosciences is committed to increase vaccine availability and affordability for the developing world and has received a $3.8 million grant from the Bill & Melinda Gates Foundation to fund this work.
Despite many advances in manufacturing technologies in recent years, cost of manufacturing can still present a significant hurdle in the global supply of essential vaccines, such as Polio and Rotavirus vaccines. The work funded by this grant will reduce manufacturing costs of these key vaccines. In its advanced cell-line experience, Batavia Biosciences collaborates with Proventus Bio and their whole genome RNAi screening technology. The RNAi screening data allows Batavia Biosciences to utilize its gene editing technology and cell line expertise. This way, a range of new cell substrates can be generated which will be assessed for its manufacturing performance. Chris Yallop (CSO Batavia Biosciences) expects that “the new cell substrates can significantly increase production yield and thus enhance vaccine availability against reduced costs”.
Menzo Havenga (CEO Batavia Biosciences) adds: “It is extremely rewarding to be working with other best in class partners on a technology development that will have such significant impact in vaccine supply for those in need”.